Elaine Ballinger received her PhD in pharmacology (’18) from Weill Cornell Graduate School of Medical Sciences, where she researched drug targets for the treatment of tuberculosis. Since joining AgonOx in 2021, she has supported the team’s work on AGX148 TIL expansion and murine tumor models.